Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer

Ovarian cancer is the 8th leading cause of cancer-related death in women. Its prognosis is poor, with diagnosis often made at an advanced stage.

Patient management has evolved in recent years with more radical surgeries and the introduction of maintenance treatment following neoadjuvant chemotherapy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ovarian Cancer Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Service de Gynécologique et d'Obstétrique - CHU de Strasbourg - France

Strasbourg, France

Location status: Recruiting

Location contact

Lise LECOINTRE, MD

CONTACT

[email protected]

33 3 88 12 75 10

Lise LECOINTRE, MD

PRINCIPAL_INVESTIGATOR

Marie LORHO, MD

SUB_INVESTIGATOR

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patient (≥18 years old)
Operated on at the HUS between January 1, 2010 and December 31, 2022
Having undergone primary or interval cytoreductive surgery
Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin

Exclusion criteria

Patiente ayant exprimé son opposition à la réutilisation de ses données à des fins de recherches scientifiques.
Autres types histologiques de cancer de l'ovaire
Stades de la maladie FIGO I, II, IIIA et IIIC
Chirurgie de clôture.

Treatment and study plan

Primary outcomes

Study of progression-free survival at 36 months

Time frame: At 36 months

Study contacts

Contact information is provided by the study sponsor or research team.

Lise LECOINTRE, MD

CONTACT

[email protected]

33 3 88 12 75 10

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: PACO

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Apr 2, 2025
Registry last updated: Apr 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting